Prediction of antibody persistency from antibody titres to natalizumab

Poul Erik H Jensen; Nils Koch-Henriksen; Finn Sellebjerg; Per S Sørensen

doi:10.1177/1352458512441688

Prediction of antibody persistency from antibody titres to natalizumab

Poul Erik H Jensen, Nils Koch-Henriksen, Finn Sellebjerg, Per S Sørensen

IKM

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

22 Citationer (Scopus)

Abstract

In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.

Originalsprog	Engelsk
Tidsskrift	Multiple Sclerosis
Vol/bind	18
Udgave nummer	10
Sider (fra-til)	1493-9
Antal sider	7
ISSN	1352-4585
DOI	https://doi.org/10.1177/1352458512441688
Status	Udgivet - 2012

Adgang til dokumentet

10.1177/1352458512441688

Citationsformater

@article{183600bb62b14854997d2659aabb86ad,

title = "Prediction of antibody persistency from antibody titres to natalizumab",

abstract = "In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.",

author = "Jensen, {Poul Erik H} and Nils Koch-Henriksen and Finn Sellebjerg and S{\o}rensen, {Per S}",

year = "2012",

doi = "10.1177/1352458512441688",

language = "English",

volume = "18",

pages = "1493--9",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "10",

}

TY - JOUR

T1 - Prediction of antibody persistency from antibody titres to natalizumab

AU - Jensen, Poul Erik H

AU - Koch-Henriksen, Nils

AU - Sellebjerg, Finn

AU - Sørensen, Per S

PY - 2012

Y1 - 2012

N2 - In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.

AB - In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.

U2 - 10.1177/1352458512441688

DO - 10.1177/1352458512441688

M3 - Journal article

C2 - 22454098

VL - 18

SP - 1493

EP - 1499

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 10

ER -